TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16195124

Group type: EXPERIMENTAL
Intervention: Night-time milk containing 10-40 ng/l melatonin, consumed daily for 8 weeks.
Number of subjects: 151

Group type: COMPARATOR
Intervention: Normal daytime milk, consumed as a control for 8 weeks.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during the first period of the crossover study.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during the later period of the crossover study.
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Night-time milk consumed during winter solstice.
Number of subjects: 151
Study: 12869401

Group type: EXPERIMENTAL
Intervention: Randomized reading of paired films from individuals one after the other (random and unknown order)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Randomized reading of all films
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Subjects randomized, sequential order known to the reader
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Subjects randomized, random order unknown to the reader, simultaneous reading on separate screens
Number of subjects: 404
Study: 10887919

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg) and Alfentanil (10 microg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg) and Vecuronium (0.1 mg/kg)
Number of subjects: 40
Study: 8629746

Group type: EXPERIMENTAL
Intervention: HBOC‐201 (45 g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control solution (Ringer's lactate)
Number of subjects: 24
Study: 1593511

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brisk walking
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neutral reading
Number of subjects: 96
Study: 3905222

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 50 mg 3 times daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proglumethacin 150 mg 3 times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 60
Study: 29982939

Group type: EXPERIMENTAL
Intervention: L‐PRF used in addition to another layer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional graft materials (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: L‐PRF
Number of subjects: 40
Study: 26435033

Group type: EXPERIMENTAL
Intervention: Insulin initiation with glargine, with or without glulisine
Number of subjects: 89
Study: 24773163

Group type: EXPERIMENTAL
Intervention: Nonharmful drinkers
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Harmful/likely dependent drinkers
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Missing a dose of HIV medications
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Inconsistent condom use
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Exchanging sex for food, money, gifts, or a place to stay
Number of subjects: 3538

Group type: EXPERIMENTAL
Intervention: Having a sexually transmitted infection symptom
Number of subjects: 3538
Study: 23134888

Group type: EXPERIMENTAL
Intervention: HSF-DHA diet (3.45 g DHA/d)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: HSF diet
Number of subjects: 88
Study: 20130968

Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluid loading (FL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR2) after fluid loading
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Passive leg rise (PLR1) in non-responders (NR)
Number of subjects: 40
Study: 19195454

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (800/100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (once or twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 0
Study: 16115248

Group type: EXPERIMENTAL
Intervention: Binaural beat audio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audio Group (identical soundtrack without binaural beats)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Intervention Group
Number of subjects: 0
Study: 12215586

Group type: EXPERIMENTAL
Intervention: Skin biopsies analyzed by electron microscopy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: COL3A1 gene analysis
Number of subjects: 21
Study: 12072853

Group type: EXPERIMENTAL
Intervention: Custom-made biomechanic shoe orthoses
Number of subjects: 146
Study: 9805325

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal elderly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal young
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Young normal participants with concurrent memory load
Number of subjects: 0
Study: 7695306

Group type: EXPERIMENTAL
Intervention: 882C87 200 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 400 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 1600 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 50 mg (elderly)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 100 mg (elderly)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 50 to 400 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 882C87 with food
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5PU (metabolite)
Number of subjects: 2
Study: 1978491

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 18

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 18
Study: 351218

Group type: EXPERIMENTAL
Intervention: Insulin treatment (adjusted dosage to achieve normoglycemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed dose of insulin
Number of subjects: 0
Study: 7039378

Group type: EXPERIMENTAL
Intervention: Ticarcillin (one 6 g dose at the start of the operation)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cephalothin (three 2 g doses given at 4 hour intervals from the start of the operation)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 28436545

Group type: EXPERIMENTAL
Intervention: Training group (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active control group (n=35)
Number of subjects: 70
Study: 26446118

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 263

Group type: COMPARATOR
Intervention: Education control condition
Number of subjects: 263
Study: 25006819

Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil (LY2140023 monohydrate)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 22664806

Group type: EXPERIMENTAL
Intervention: 64-slice multidetector computed tomography (MDCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive coronary angiography
Number of subjects: 0
Study: 20356721

Group type: EXPERIMENTAL
Intervention: Parental reports of fatty acid deficiency symptoms (FADS)
Number of subjects: 450
Study: 18372395

Group type: EXPERIMENTAL
Intervention: Solabegron 50 mg twice daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Solabegron 200 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15703932

Group type: COMPARATOR
Intervention: (99m)Tc‐sestamibi in euthyroid volunteers (EVs)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in Graves' disease (GD) patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in hypertrophic Hashimoto's thyroiditis (HHT) patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐sestamibi in atrophic Hashimoto's thyroiditis (AHT) patients
Number of subjects: 90
Study: 12875702

Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone once daily plus sulphonylurea
Number of subjects: 198

Group type: COMPARATOR
Intervention: 0.5 g metformin twice daily plus sulphonylurea
Number of subjects: 198
Study: 10563066

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.05 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg and 0.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin and Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 0
Study: 8887768

Group type: EXPERIMENTAL
Intervention: High lactate (HL)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Moderate lactate (C)
Number of subjects: 7
Study: 1957618

Group type: EXPERIMENTAL
Intervention: Milk cereal fortified with ferrous fumarate (7.5 mg/100 g)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Milk cereal fortified with ferric-pyrophosphate (7.5 mg/100 g)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Milk cereal without iron fortification
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fortified cereals (both types)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All supplemented groups
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 130
Study: 6359383

Group type: EXPERIMENTAL
Intervention: ampicillin plus cloxacillin (2 g of each daily for 6 days)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: ticarcillin (5 g X 12, 8‐hourly)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: carbenicillin (10 g X 12, 8‐hourly)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: short carbenicillin prophylaxis (1 day)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: clindamycin (900 mg, 4 daily doses)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: clindamycin plus netilmicin (90 mg, 4 daily doses)
Number of subjects: 429

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 429
Study: 31206956

Group type: EXPERIMENTAL
Intervention: 0.2 mL/kg 24% sucrose
Number of subjects: 129

Group type: COMPARATOR
Intervention: 0.5 mL/kg 24% sucrose
Number of subjects: 129
Study: 29230663

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 µg/kg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 6 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF 100 µg/kg and 6 mg
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 569
Study: 27222508

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study: 25234339

Group type: EXPERIMENTAL
Intervention: 500 mg/d of RRR‐α‐tocopherol
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 500 mg/d of mixed tocopherols
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 500 mg/d of vitamin C
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 1000 mg/d of grape‐seed polyphenols
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and polyphenols
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo (neither vitamin C nor polyphenols)
Number of subjects: 127
Study: 22391079

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 μg, daily for 1 year
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 μg, daily for 1 year
Number of subjects: 96
Study: 19685292

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RCT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both RT and RCT
Number of subjects: 64
Study: 18629723

Group type: EXPERIMENTAL
Intervention: Quest plus NRT
Number of subjects: 346

Group type: COMPARATOR
Intervention: Active control plus NRT
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Quest plus placebo patch
Number of subjects: 346
Study: 15773861

Group type: EXPERIMENTAL
Intervention: High-volume exercise group (HEG, n=20, 8.4 h week(‐1))
Number of subjects: 41

Group type: COMPARATOR
Intervention: Medium-volume exercise group (MEG, n=21, 6 h week(‐1))
Number of subjects: 41
Study: 11807358

Group type: EXPERIMENTAL
Intervention: Seprafilm membrane (hyaluronic acid-carboxymethylcellulose)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no Seprafilm membrane)
Number of subjects: 71
Study: 10450295

Group type: EXPERIMENTAL
Intervention: DASH dietary patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menu design and food production methodologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutrient database and menu evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final menu adjustments
Number of subjects: 0
Study: 8914905

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% or 0.5%) with epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine (1% or 2%) with epinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 100

Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 100
Study: 1931628

Group type: EXPERIMENTAL
Intervention: Radiation and misonidazole (PLUS MISO)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiation alone (NO MISO)
Number of subjects: 58
Study: 6166691

Group type: EXPERIMENTAL
Intervention: Interferon alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined interferon and adenine arabinoside
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (spontaneous decrease)
Number of subjects: 32
Study: 30591073

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27753145

Group type: EXPERIMENTAL
Intervention: WSE + TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: WSE + placebo TENS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 25543426

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate injection at auricular points (0.25 mL at each point)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subcutaneous fentanyl citrate injection in the deltoid muscle (1 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subcutaneous sodium chloride injection in the deltoid muscle (1 mL)
Number of subjects: 90
Study: 22351892

Group type: EXPERIMENTAL
Intervention: ω‐3 group (500‐mg daily fish oil supplement and canola-based margarines and cooking oil)
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control group (500‐mg daily sunflower oil supplement and ω‐6 fatty acid-rich margarines and cooking oil)
Number of subjects: 616
Study: 20691764

Group type: EXPERIMENTAL
Intervention: Training with the left hand followed by nocturnal sleep (training at 8 pm and retrieval test at 8 am)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training with the left hand followed by daytime wakefulness (training at 8 am and retrieval test at 8 pm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with the left hand
Number of subjects: 0
Study: 19000540

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study: 15940616

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 12837811

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 every 3 weeks (DC)
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 and carboplatin area under the curve of 6 mg/mL * min every 3 weeks (DCb)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m2/wk and cisplatin 100 mg/m2 every 4 weeks (VC)
Number of subjects: 1218
Study: 10338227

Group type: EXPERIMENTAL
Intervention: Educational program on test ordering standards
Number of subjects: 0
Study: 8619702

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia
Number of subjects: 399

Group type: COMPARATOR
Intervention: Intermittent aortic cross-clamping
Number of subjects: 399
Study: 1751269

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 1 ml kg‐1 with ketamine 0.5 mg kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.25% bupivacaine 1 ml kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: ketamine 0.5 mg kg‐1 with normal saline 1 ml kg‐1
Number of subjects: 50
Study: 6762741

Group type: EXPERIMENTAL
Intervention: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) plus intradermic BCG
Number of subjects: 30
Study: 31973599

Group type: EXPERIMENTAL
Intervention: Implementation package (experimental group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 30859956

Group type: EXPERIMENTAL
Intervention: 1-day initiation regimen (ALNCD + 30mg oral aripiprazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 21-day oral aripiprazole regimen
Number of subjects: 0
Study: 28109729

Group type: EXPERIMENTAL
Intervention: Montelukast sodium and mometasone furoate (MF) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Montelukast only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) only
Number of subjects: 30
Study: 25772444

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) at doses of 0.4, 0.6, or 0.8 U/kg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Biphasic insulin aspart 30 (control)
Number of subjects: 33
Study: 23122917

Group type: EXPERIMENTAL
Intervention: cathodal tDCS (2 mA, 25 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 40
Study: 22059179

Group type: EXPERIMENTAL
Intervention: Telehealth-PR
Number of subjects: 409

Group type: COMPARATOR
Intervention: Standard-PR
Number of subjects: 409
Study: 19340550

Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-sympathomimetic)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Hypotensive individuals
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normotensive control persons
Number of subjects: 54
Study: 16832639

Group type: EXPERIMENTAL
Intervention: Spa water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tap water therapy at 37 degrees C for 20 min a day, 5 days a week, for 2 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of spa water therapy vs tap water therapy
Number of subjects: 52
Study: 15539773

Group type: EXPERIMENTAL
Intervention: Avonex (interferon beta‐1a)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin)
Number of subjects: 80
Study: 11328217

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 245

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 245
Study: 9389900

Group type: EXPERIMENTAL
Intervention: Plasma lutein
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Change in plasma lutein
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Plasma retinol
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 191
Study: 7642826

Group type: EXPERIMENTAL
Intervention: Mistuned fourth harmonic of a 90‐ms 12‐harmonic 155‐Hz fundamental complex tone preceded by four 90‐ms tones at the same frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mistuned component presented ipsilaterally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mistuned component presented contralaterally
Number of subjects: 0
Study: 2746125

Group type: EXPERIMENTAL
Intervention: Catgut sutures
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Molecular studies of collagen proteins
Number of subjects: 137
Study: 769147

Group type: EXPERIMENTAL
Intervention: Phase-release aspirin tablets given twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Aspirin B.P. tablets given four times daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Phase-release aspirin tablets
Number of subjects: 36
Study: 30707651

Group type: EXPERIMENTAL
Intervention: Telementoring support (TMS)
Number of subjects: 33
Study: 26348699

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (GCBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine Psychosocial Rehabilitation (RPR) with access to Individual CBT (ICBT)
Number of subjects: 88
Study: 23754735

Group type: EXPERIMENTAL
Intervention: 10 mg twice daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 20 mg twice daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 30 mg twice daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 5 or 7.5 mg twice daily
Number of subjects: 378
Study: 21788353

Group type: EXPERIMENTAL
Intervention: docetaxel + prednisone + custirsen (DPC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: mitoxantrone + prednisone + custirsen (MPC)
Number of subjects: 42
Study: 18420663

Group type: COMPARATOR
Intervention: Standardised usual care (control)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Less intensive self monitoring
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: More intensive self monitoring
Number of subjects: 453
Study: 17065671

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 1129
Study: 14499101

Group type: EXPERIMENTAL
Intervention: Family participation program in basic care for critically ill patients
Number of subjects: 117
Study: 10856103

Group type: EXPERIMENTAL
Intervention: IRS-IV therapy (intensified therapy with a doubling of cyclophosphamide or ifosfamide equivalent dosing per cycle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRS-IV therapy
Number of subjects: 0
Study: 8635369

Group type: EXPERIMENTAL
Intervention: Flunitrazepam, 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam, 0.25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0